Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.
BACKGROUND
Protease inhibitors are known to alter the lipid profiles in subjects treated for HIV/AIDS. However, the magnitude of this effect on plasma lipoproteins and lipids has not been adequately quantified.


OBJECTIVE
To estimate the changes in plasma lipoproteins and triglycerides occurring within 12 months of initiating PI-based antiretroviral therapy among HIV/AIDS afflicted subjects.


METHODS
We included all antiretroviral naive HIV-infected persons treated at St-Paul's Hospital, British Columbia, Canada, who initiated therapy with protease inhibitor antiretroviral (ARV) drugs between August 1996 and January 2002 and who had at least one plasma lipid measurement. Longitudinal associations between medication use and plasma lipids were estimated using mixed effects models that accounted for repeated measures on the same subjects and were adjusted for age, sex, time dependent CD4+ T-cell count, and time dependent cumulative use of non-nucleoside reverse transcriptase inhibitors and adherence. The cumulative number of prescriptions filled for PIs was considered time dependent. We estimated the changes in the 12 months following any initiation of a PI based regimen.


RESULTS
A total of 679 eligible subjects were dispensed nucleoside analogues and PI at the initiation of therapy. Over a median 47 months of follow-up (interquartile range (IQR): 29-62), subjects had a median of 3 (IQR: 1-6) blood lipid measurements. Twelve months after treatment initiation of PI use, there was an estimated 20% (95% confidence interval: 17% - 24%) increase in total cholesterol and 22% (12% - 33%) increase in triglycerides.


CONCLUSIONS
Twelve months after treatment initiation with PIs, statistically significant increases in total cholesterol and triglycerides levels were observed in HIV-infected patients under conditions of standard treatment. Our results contribute to the growing body of evidence implicating PIs in the development of blood lipid abnormalities. In conjunction with the predominance or men, high rates of smoking, and aging of the treated HIV-positive population, elevated lipoproteins and triglycerides may mean that patients such as these are at elevated risk for cardiovascular events in the future.
Levy
Adrian R
AR
Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada. alevy@interchange.ubc.ca
McCandless
Lawrence
L
Harrigan
P Richard
PR
Hogg
Robert S
RS
Bondy
Greg
G
Iloeje
Uchenna H
UH
Mukherjee
Jayanti
J
Montaner
Julio S
JS
D000328:Adult; D002784:Cholesterol / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006678:HIV / Q000187:drug effects* / Q000502:physiology*; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy* / Q000201:enzymology / Q000821:virology; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
D011480:Protease Inhibitors; D014280:Triglycerides; D002784:Cholesterol